UWELL CLOUD YOU JIAN YUN
Drugs & Devices

Hernexeos zongertinib

宗格替尼

Lung cancer

Drug Class

HER2 tyrosine kinase inhibitor

Mechanism

Selectively inhibits the kinase domain of HER2 while sparing wild-type EGFR, blocking downstream oncogenic signaling.

Approved Indication

Advanced HER2 tyrosine kinase domain-mutated non-squamous non-small cell lung cancer, per its FDA approval.

What This Means For Patients

Hernexeos is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

  • FDAApproved (2025) — Sources

Pivotal Clinical Evidence

Sources

This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.

Sariyah Ahmad
Active Triage Officer

Welcome to Uwell Cloud. Connecting from Malaysia, Indonesia, or Thailand? Ask me about visa-free travel and stem cell medical programs in Boao Lecheng.